| Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus MJ Pena, HJ Lambers Heerspink, ME Hellemons, T Friedrich, G Dallmann, ... Diabetic Medicine 31 (9), 1138-1147, 2014 | 150 | 2014 |
| Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial E Meijer, FW Visser, RMM van Aerts, CJ Blijdorp, NF Casteleijn, ... Jama 320 (19), 2010-2019, 2018 | 117 | 2018 |
| A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes MJ Pena, A Heinzel, G Heinze, A Alkhalaf, SJL Bakker, TQ Nguyen, ... PLoS One 10 (5), e0120995, 2015 | 68 | 2015 |
| Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes Mellitus G Mayer, HJL Heerspink, C Aschauer, A Heinzel, G Heinze, A Kainz, ... Diabetes care, dc162202, 2017 | 61 | 2017 |
| Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT on Morbidity and Mortality in Type 2 Diabetes Patients With Nephropathy A Bidadkosh, SPH Lambooy, HJ Heerspink, MJ Pena, RH Henning, ... Diabetes care, dc162175, 2017 | 50* | 2017 |
| Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes MJ Pena, D de Zeeuw, H Mischak, J Jankowski, R Oberbauer, ... Nephrology Dialysis Transplantation 30 (suppl_4), iv86-iv95, 2015 | 50 | 2015 |
| Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease MJ Pena, H Mischak, HJL Heerspink Diabetologia 59 (9), 1819-1831, 2016 | 44 | 2016 |
| Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes MJ Pena, J Jankowski, G Heinze, M Kohl, A Heinzel, SJL Bakker, ... Journal of hypertension 33 (10), 2123-2132, 2015 | 42 | 2015 |
| Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease MJ Pena, P Stenvinkel, M Kretzler, D Adu, SK Agarwal, J Coresh, ... Kidney International Supplements 7 (2), 107-113, 2017 | 29 | 2017 |
| Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus MJ Pena, A Heinzel, P Rossing, HH Parving, G Dallmann, K Rossing, ... Journal of translational medicine 14 (1), 203, 2016 | 25 | 2016 |
| The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy MJ Pena, D de Zeeuw, D Andress, JJ Brennan, R Correa‐Rotter, B Coll, ... Diabetes, Obesity and Metabolism 19 (5), 749-753, 2017 | 20 | 2017 |
| Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives JK de Vries, A Levin, F Loud, A Adler, G Mayer, MJ Pena Diabetes, Obesity and Metabolism 20, 24-29, 2018 | 19 | 2018 |
| Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study EM Apperloo, MJ Pena, D de Zeeuw, P Denig, HJL Heerspink Diabetes, Obesity and Metabolism 20 (6), 1377-1383, 2018 | 12 | 2018 |
| N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk NMA Idzerda, F Persson, MJ Pena, BM Brenner, P Brunel, N Chaturvedi, ... Diabetes, Obesity and Metabolism 20 (12), 2899-2904, 2018 | 11 | 2018 |
| Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; apost hoc analysis of the PLANET trials N Idzerda, MJ Pena, HH Parving, D de Zeeuw, HJL Heerspink Nephrology Dialysis Transplantation, 2018 | 11 | 2018 |
| Personalized medicine in diabetic kidney disease: a novel approach to improve trial design and patient outcomes NMA Idzerda, MJ Pena, HJL Heerspink Current opinion in nephrology and hypertension 27 (6), 426-432, 2018 | 7 | 2018 |
| Non-LDL dyslipidemia is prevalent in the young and determined by lifestyle factors and age: The LifeLines cohort JK de Vries, JW Balder, MJ Pena, P Denig, AJ Smit Atherosclerosis 274, 191-198, 2018 | 6 | 2018 |
| Future and Novel Compounds in the Treatment of Diabetic Nephropathy NMA Idzerda, MJ Pena, D de Zeeuw, HJL Heerspink Diabetic Nephropathy, 515-539, 2019 | 4 | 2019 |
